GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Margin of Safety % (DCF Earnings Based)

Hikma Pharmaceuticals (LSE:HIK) Margin of Safety % (DCF Earnings Based) : 24.70% (As of Oct. 31, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2024-10-31), Hikma Pharmaceuticals's Predictability Rank is 4.5-Stars. Hikma Pharmaceuticals's intrinsic value calculated from the Discounted Earnings model is £25.26 and current share price is £19.02. Consequently,

Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is 24.70%.

Competitive Comparison of Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


Hikma Pharmaceuticals Margin of Safety % (DCF Earnings Based) Calculation

Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(25.26-19.02)/25.26
=24.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

Hikma Pharmaceuticals Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Margin of Safety % (DCF Earnings Based)
Comparable Companies
LSE:HCM LSE:INDV LSE:AGY LSE:APH LSE:ANCR LSE:EAH LSE:STX LSE:CEL LSE:PXS LSE:N4P ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA XSWX:SDZ NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany
Address
1 New Burlington Place, London, GBR, W1S 2HR
Website
https://www.hikma.com
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines